SCHEMBL1593340

SCHEMBL1593340

CCOc1ccccc1-n1c(CN2CCCN(C)CC2)nc2cc(F)ccc2c1=O

nearest known ligand 0.75

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 11/20 0.75
HTR7 P34969 8/20 0.57
ALDH1A1 P00352 2/20 0.54
LMNA P02545 1/20 0.54
PKM P14618 1/20 0.54
TSHR P16473 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HTR1A P08908 3/20 0.53
DRD2 P14416 2/20 0.51
HTR2C P28335 2/20 0.51
HTR2A P28223 1/20 0.51
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1593540 0.90 HIF1A (0.74) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL1593598 0.90 HIF1A (0.92) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL1593685 0.90 HIF1A (0.70) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL1592775 0.88 HIF1A (0.60) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL1593047 0.86 HIF1A (0.65) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL12610265 0.86 HIF1A (1.00) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL4522145 0.86 HIF1A (0.75) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL1592835 0.84 HIF1A (0.64) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL4527044 0.84 HIF1A (0.72) HIF1AHTR7ALDH1A1LMNAPKM
SCHEMBL15368090 0.80 HIF1A (0.59) HIF1AHTR7ALDH1A1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof MKI67, MCL1, HCCS HIF1A 1381/4885HTR7 828/4885ALDH1A1 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.